SE7910568L - Guanidinotiazolforeningar och forfarande for framstellning derav - Google Patents

Guanidinotiazolforeningar och forfarande for framstellning derav

Info

Publication number
SE7910568L
SE7910568L SE7910568A SE7910568A SE7910568L SE 7910568 L SE7910568 L SE 7910568L SE 7910568 A SE7910568 A SE 7910568A SE 7910568 A SE7910568 A SE 7910568A SE 7910568 L SE7910568 L SE 7910568L
Authority
SE
Sweden
Prior art keywords
group
lower alkyl
alkyl group
hydrogen atom
guanidinotiazolo
Prior art date
Application number
SE7910568A
Other languages
English (en)
Other versions
SE444317B (sv
Inventor
Y Hirata
I Yanagisawa
Y Ishii
S Tsukamoto
N Ito
Y Isomura
M Takeda
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14232166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE7910568(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of SE7910568L publication Critical patent/SE7910568L/sv
Publication of SE444317B publication Critical patent/SE444317B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE7910568A 1979-08-02 1979-12-21 Nya guanidinotiazolforeningar samt farmaceutiska kompositioner derav SE444317B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54098906A JPS6056143B2 (ja) 1979-08-02 1979-08-02 アミジン誘導体ならびにその製造法

Publications (2)

Publication Number Publication Date
SE7910568L true SE7910568L (sv) 1981-02-03
SE444317B SE444317B (sv) 1986-04-07

Family

ID=14232166

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7910568A SE444317B (sv) 1979-08-02 1979-12-21 Nya guanidinotiazolforeningar samt farmaceutiska kompositioner derav

Country Status (12)

Country Link
US (1) US4283408A (sv)
JP (1) JPS6056143B2 (sv)
CA (2) CA1134836A (sv)
CH (1) CH648027A5 (sv)
DE (1) DE2951675C2 (sv)
ES (1) ES487381A0 (sv)
FR (1) FR2462431B1 (sv)
GB (1) GB2055800B (sv)
IT (1) IT1119641B (sv)
NL (2) NL180420C (sv)
PH (1) PH15657A (sv)
SE (1) SE444317B (sv)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ186965A (en) * 1977-04-20 1980-02-21 Ici Ltd Guanidino derivatives and pharmaceutical compositions
PH16099A (en) * 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
GR71929B (sv) * 1979-11-13 1983-08-19 Ici Ltd
DE3168031D1 (en) * 1980-07-30 1985-02-14 Ici Plc Guanidine derivatives
US4382090A (en) * 1980-10-02 1983-05-03 Eli Lilly And Company N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds
IN158869B (sv) * 1981-03-18 1987-02-07 Ici Plc
EP0067508B1 (en) * 1981-05-18 1985-10-30 Imperial Chemical Industries Plc Amidine derivatives
DE3238867A1 (de) * 1982-10-20 1984-04-26 Ludwig Heumann & Co GmbH, 8500 Nürnberg Heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPS59104370A (ja) * 1982-12-03 1984-06-16 Kotobuki Seiyaku Kk チアゾ−ル誘導体及びその製造方法
JPS59227870A (ja) * 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4497810A (en) * 1983-10-14 1985-02-05 Merck & Co., Inc. Thiatriazine dioxides as gastric anti-secretory agents
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
CA1269382A (en) * 1984-04-18 1990-05-22 Jose A. Ortiz Anti-ulceric sulfonamidines
US4560690A (en) * 1984-04-30 1985-12-24 Pfizer Inc. 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents
JPS6160673A (ja) * 1984-08-30 1986-03-28 Yamanouchi Pharmaceut Co Ltd グアニジノチアゾ−ル誘導体の製造法
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
DE3644246A1 (de) * 1986-06-20 1987-12-23 Uriach & Cia Sa J Verfahren zur herstelung von 3-(((2-((aminoiminomethyl)-amino)-4-thiazolyl)-methyl)-thio)-n-(aminosulfonyl)-propanimidamid
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
ES2008810A6 (es) * 1988-07-18 1989-08-01 Marga Investigacion Procedimiento de preparacion de derivados de n-sulfamil-propionamidina.
US5428033A (en) 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
US5667794A (en) * 1995-05-02 1997-09-16 Merck & Co., Inc. Heartburn treatment
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
KR0168978B1 (ko) * 1995-07-12 1999-01-15 김종인 헤테로고리 접합 티아졸 유도체
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US5731442A (en) * 1997-03-11 1998-03-24 Albemarle Corporation Synthesis of thiazole derivatives
US5856500A (en) * 1997-03-11 1999-01-05 Albemarle Corporation Synthesis of thiazole derivatives
US6552047B2 (en) * 1998-11-17 2003-04-22 Nitromed, Inc. H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US7163705B2 (en) 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
WO2001021156A1 (en) * 1999-04-06 2001-03-29 Wm. Wrigley Jr. Company Pharmaceutical chewing gum formulations
US7935362B2 (en) 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
AU3885201A (en) 1999-09-20 2001-04-24 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
US7115288B2 (en) 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
WO2006071659A1 (en) * 2004-12-29 2006-07-06 Trustees Of Boston University Delivery of h2 antagonists
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
DK2043637T3 (da) 2006-07-18 2012-05-07 Horizon Pharma Usa Inc Fremgangsmåder og medikamenter til administrering af ibuprofen
EP2063873A2 (en) * 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20090069395A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched famotidine
EP3090739A1 (en) 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions composed of naproxen sodium and nizatidine
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2010132509A2 (en) 2009-05-11 2010-11-18 Agraquest, Inc. Compounds derived from muscodor fungi
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
WO2015002150A1 (ja) * 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
EP2929884A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
EP2942058A1 (en) 2014-05-09 2015-11-11 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
TR201618765A2 (tr) 2016-12-16 2018-07-23 Imuneks Farma Ilac Sanayi Ve Ticaret Anonim Sirketi Ağrı ve enflamasyonun tedavisi için steroid olmayan anti-enflamatuvar ilaçlar ve H2 reseptörü antagonisti kombinasyonları.
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
JP2023534810A (ja) 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer
GB2644313A (en) 2024-09-27 2026-04-01 Novumgen Ltd An orodispersible tablet of Famotidine and its process of preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338169A (en) * 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
NZ186965A (en) * 1977-04-20 1980-02-21 Ici Ltd Guanidino derivatives and pharmaceutical compositions
US4165378A (en) * 1977-04-20 1979-08-21 Ici Americas Inc. Guanidine derivatives of imidazoles and thiazoles

Also Published As

Publication number Publication date
FR2462431B1 (fr) 1985-07-26
SE444317B (sv) 1986-04-07
FR2462431A1 (fr) 1981-02-13
DE2951675A1 (de) 1981-02-05
IT7969498A0 (it) 1979-12-28
ES8100281A1 (es) 1980-11-01
NL7909321A (nl) 1981-02-04
NL180420C (nl) 1987-02-16
NL930038I1 (nl) 1993-08-02
NL930038I2 (nl) 1993-10-01
JPS5622770A (en) 1981-03-03
NL180420B (nl) 1986-09-16
JPS6056143B2 (ja) 1985-12-09
CH648027A5 (de) 1985-02-28
PH15657A (en) 1983-03-11
DE2951675C2 (de) 1982-07-01
GB2055800B (en) 1983-05-11
ES487381A0 (es) 1980-11-01
US4283408A (en) 1981-08-11
CA1134836A (en) 1982-11-02
IT1119641B (it) 1986-03-10
GB2055800A (en) 1981-03-11
CA1222763B (en) 1987-06-09

Similar Documents

Publication Publication Date Title
ES8100281A1 (es) Un procedimiento para la preparacion de un compuesto de guanidinotiazol
FI921451A0 (fi) Ny linker foer bioaktiva medel.
ES540469A0 (es) Procedimiento para la obtencion de derivados de nitrometile-no
ES8401035A1 (es) "metodo de preparar compuestos benzoheterociclicos".
SE8001691L (sv) Guanidintiazolforeningar, forfarande for framstellning av dem och lekemedel som innehaller dem
ES8200857A1 (es) Procedimiento de preparacion de un nuevo eter basico o de una sal de adicion acida o sal cuaternaria del mismo,farma- ceuticamente aceptable
ES465340A1 (es) Procedimiento para la obtencion de derivados de amino-azu- car.
AU562583B2 (en) Substituted 1,4-dihydropyridines
IL106387A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL74117A0 (en) Methylenediphosphonic acid derivatives,their preparation and pharmaceutical compositions containing them
ES508343A0 (es) "procedimiento para la preparacion de nuevas pirimido (5,4-d) pirimidinas trisustituidas".
SE8006953L (sv) Heterocykliska foreningar
DK62281A (da) Fremgangsmaade til fremstilling af triazoloquinazolinonderivater
ES8406458A1 (es) Procedimiento para preparar derivados bencilidenicos sulfurados
GEP19970667B (en) Method of producing guanidinothiazole compounds
SE7902724L (sv) Substituerade n-iminometylpiperidiner
SE8301928D0 (sv) Nya karbapenemderivat och forfarande for framstellning derav
SE7905940L (sv) Nya derivat av daunorubicin, framstellning av desamma och farmaceutiska kompositioner innehallande desamma
DK160090C (da) Analogifremgangsmaade til fremstilling af benzhydr ylsulfinylethylaminderivat
DK104488A (da) Acetamider afledt af 2,3-dihydro-3-phenyl-2-benzofuranon, fremgangsmaader til deres fremstilling og farmaceutiske midler indeholdende dem
DK573981A (da) Fremgangsmaade til fremstilling af cis-c-3",c4"-carbonatderivater af o-demethyl-oleandomycin og mellemprodukter herfor
ES2019841A6 (es) Procedimiento para preparar derivados de tieno-triazolo-diazepina.

Legal Events

Date Code Title Description
SPCF Application for supplementary protection certificate filed

Free format text: 7910568

NAL Patent in force

Ref document number: 7910568-0

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9490114, 870327, EXPIRES: 20000709

SPCG Supplementary protection certificate granted

Free format text: 9490114, 870327, EXPIRES: 20020326

NUG Patent has lapsed

Ref document number: 7910568-0

Format of ref document f/p: F